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Abstract
Background: Performing a test of cure (TOC) could demonstrate success or failure of antimicrobial treatment of
Chlamydia trachomatis infection, but recommendations for the timing of a TOC using nucleic acid amplification
tests (NAATs) are inconsistent. We assessed time to clearance of C. trachomatis after treatment, using modern RNA-
and DNA-based NAATs.
Methods: We analysed data from patients with a C. trachomatis and Neisseria gonorrhoeae coinfection who visited the
STI Clinic Amsterdam, The Netherlands, from March through October 2014. After treatment with ceftriaxone plus either
azithromycin or doxycycline, patients self-collected anal, vaginal or urine samples during 28 consecutive days. Samples
were analysed using an RNA-based NAAT (Aptima Combo 2) and a DNA-based NAAT (Cobas 4800 CT/NG). We defined
clearance as three consecutive negative results, and defined “blips” as isolated positive results following clearance.
Results: We included 23 patients with C. trachomatis and N. gonorrhoeae coinfection. All patients cleared C.
trachomatis during follow-up, and we observed no reinfections. The median time to clearance (range) was 7 days
(1–13) for RNA, and 6 days (1–15) for DNA. Ninety-five per cent of patients cleared RNA at day 13, and DNA at day 14.
The risk of a blip after clearance was 4.4 % (RNA) and 1.7 % (DNA).
Conclusions: If a TOC for anogenital chlamydia is indicated, we recommend performing it at least 14 days after
initiation of treatment, when using modern RNA- and DNA-based assays. A positive result shortly after 14 days
probably indicates a blip, rather than a treatment failure or a reinfection.
Keywords: Chlamydia trachomatis, Neisseria gonorrhoeae, Antimicrobial resistance, Nucleic acid amplification test, Test
of cure
Background
Chlamydia trachomatis is the most common bacterial
sexually transmitted infection (STI) globally, leading to
late sequelae like pelvic inflammatory disease and infer-
tility [1, 2]. Currently, the first-choice treatment for ano-
genital chlamydia consists of a single 1000 mg dose of
azithromycin, or 100 mg doxycycline twice daily for
7 days [3, 4]. No resistance of C. trachomatis to either of
these drugs has been reported, and a recent randomized
controlled trial suggested no inferiority of azithromycin
(97 % effective) compared to doxycycline (100 % effective)
in urogenital chlamydia infections [5]. However, some
studies voice concern about the efficacy of azithromycin
as first-choice treatment for anorectal chlamydia [6–9].
Persisting C. trachomatis infections could be detected by
performing a test of cure (TOC) after treatment. Current
chlamydia treatment guidelines recommend a TOC
between 3 and 4 weeks after initiation of treatment, in cer-
tain patient groups or when symptoms persist [4, 7, 10].
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However, up to 90 % of chlamydia infections are asymp-
tomatic, which could lead to persisting infections
remaining undetected [4, 11, 12]. Previous reports on the
appropriate timing of a TOC using molecular methods are
inconsistent, and show (intermittent) persistence of C. tra-
chomatis nucleic acids between 0 and 42 % up to 51 days
after treatment [9, 13–19]. Recently, we performed a pro-
spective cohort study on time to clearance for N. gonor-
rhoeae, using modern RNA- and DNA-based nucleic acid
amplification tests (NAATs) [20]. Thirty-seven per cent of
the included patients were also coinfected with C. tracho-
matis. As this study has results of 28 consecutive days for
both RNA and DNA, we evaluated the appropriate timing
of TOC for anogenital C. trachomatis infections in these
coinfected patients.
Methods
Study population and procedure
In a previously performed cohort study we included pa-
tients with anogenital N. gonorrhoeae infection, who vis-
ited the STI Outpatient Clinic in Amsterdam, The
Netherlands, from March through October 2014 [20].
We collected follow-up data and samples for only one
infected anatomical site. The Academic Medical Center
Amsterdam medical ethics committee approved the ori-
ginal cohort study (NL45935.018.13), and all patients
provided written informed consent. For the current ana-
lysis, only patients coinfected with C. trachomatis were
included from the cohort.
All patients had received routine treatment for N.
gonorrhoeae and C. trachomatis coinfection, consisting
of a single intramuscular dose of 500 mg ceftriaxone,
plus one oral dose of azithromycin 1000 mg in case of
urogenital infection, or doxycycline 100 mg twice daily
for at least 7 days in case of anorectal infection. Partici-
pants self-collected urine, anal or vaginal NAAT sam-
ples: one for RNA-based and one for DNA-based
NAAT. Samples were collected pre-treatment and subse-
quently daily for 28 consecutive days after treatment.
We requested participants to abstain from sexual con-
tact or use condoms, refrain from vaginal or rectal
douching and keep a study diary. At the end-of-study
visit (within 35 days of inclusion) a nurse collected sam-
ples from the designated anatomical site for both
NAATs.
NAAT testing for C. trachomatis
Samples for the RNA-based NAAT were tested using
the Aptima Combo 2 assay for C. trachomatis and N.
gonorrhoeae (Hologic, San Diego, California). Test sensi-
tivity is 93–98 % and specificity is >99 % [21–23].
Equivocal results were retested using the Aptima CT
assay (Hologic). We considered repeatedly equivocal
results as positive and excluded samples with repeatedly
invalid results.
Samples for DNA-based NAAT were tested using the
Cobas 4800 CT/NG assay for C. trachomatis and N.
gonorrhoeae (Roche, Basel, Switzerland), and reported as
either negative or positive with corresponding cycle
threshold (Ct) value. Test sensitivity is 87–97 % and spe-
cificity is >99 % [22–24]. Pre-treatment samples with
discrepant RNA and DNA results were retested, using
the Aptima CT assay (Hologic) for RNA samples, and
the Abbott RealTime CT/NG assay (Abbott, Abbott
Park, Illinois) for DNA samples.
Statistical analysis
The primary endpoint, clearance of C. trachomatis using
RNA- or DNA-based NAAT, was defined as three or
more consecutive negative results following a positive
result. We allowed one missing sample between the last
positive and the first negative result. Reinfection was de-
fined as positive test results on three or more consecu-
tive days after clearance; tests had to be positive for both
RNA and DNA on at least 1 day. To analyse differences
we compared patients grouped by anatomical site using
Chi-square, Fisher’s exact or Kruskal-Wallis testing.
Time to clearance was analysed with Kaplan-Meier
curves, log-rank testing and Cox regression analysis. If
we could not determine the exact day of clearance due
to missing samples, the patient was excluded from this
analysis.
The secondary endpoint, intermittent presence of
RNA or DNA (“blip”), was defined as a positive test fol-
lowing clearance, not due to reinfection. Only positive
results after the three consecutive negative tests results,
used to define clearance, were eligible as a blip. We used
logistic regression with generalized estimated equation
(GEE) models to identify characteristics associated with
blips. All analyses were performed using Stata (version
13; StataCorp, College Station, Texas).
Results
Participants
Out of 462 patients with anogenital gonorrhoea diag-
nosed at our STI clinic from March through October
2014, 77 were included in the original cohort. Twenty-
six patients (34 %) had a coinfection with C. trachomatis
of whom three were lost to follow-up. The remaining 23
patients were included in the current analysis.
Baseline characteristics
We included nine women, all with endocervical infec-
tions, and 14 men, of whom seven had a urethral and
seven a rectal infection; 71 % were men who have sex
with men (MSM, Table 1). The median age was 24 years
(interquartile range [IQR]: 20–35 years); women were
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significantly younger (median 20 years) compared to
men (median 32 years, P < 0.001). Five men (22 %) were
HIV-positive, and four (80 %) were on antiretroviral
therapy, of whom three had CD4
+ cell counts of ≥500
cells/mm3. A previous chlamydia infection was reported
by 12 patients (52 %), and 13 (57 %) currently experi-
enced symptoms. The median time between diagnosis
and inclusion was 8 days (range 0–12). At inclusion 16
patients (70 %) received ceftriaxone with azithromycin,
and seven (30 %) received ceftriaxone with doxycycline.
Behaviour after inclusion
The median number of collected samples was 28
(range 25–28, Table 2). Forty-eight per cent of pa-
tients missed at least one sample. Rectal or vaginal
douching was reported by four of 16 patients with
rectal or endocervical chlamydia (25 %). Sexual con-
tact at some point during the 28 days of follow-up
was reported by 12 patients (52 %), and condomless
sex by five patients (22 %).
Clearance of C. trachomatis RNA and DNA
During the 28 days of follow-up all patients cleared C.
trachomatis RNA, and none experienced a reinfection
(Table 2). Because of missing samples in the days around
clearance, we could not determine the exact day of clear-
ance for two patients. The median time to clearance for
the remaining 21 patients was 7 days (range 1–13), and
95 % of patients had cleared RNA at day 13 (Fig. 1a).
One patient was post-hoc excluded from the DNA ana-
lysis because of a negative pre-treatment DNA result for
C. trachomatis. All other patients cleared C. trachomatis










Total 23 7 (30.4) 7 (30.4) 9 (39.1)
Gender
Male 14 (60.9) 7 (100.0) 7 (100.0) 0 (0.0)
Female 9 (39.1) 0 (0.0) 0 (0.0) 9 (100.0)
Median age, in years (IQR) 24 (20–35) 29 (24–35) 40 (24–44) 20 (19–23) 0.003
Ethnicity 1.00
Dutch 11 (47.8) 3 (42.9) 4 (57.1) 4 (44.4)
Non-Dutch 12 (52.2) 4 (57.1) 3 (42.9) 5 (55.6)
Sexual risk group
MSM 10 (43.5) 3 (42.9) 7 (100.0) 0 (0.0)
Hetero male 4 (17.4) 4 (57.1) 0 (0.0) 0 (0.0)
Female 9 (39.1) 0 (0.0) 0 (0.0) 9 (100.0)
HIV positive 5 (21.7) 1 (14.3) 4 (57.1) 0 (0.0) 0.02
Using cART 4 (80.0) 0 (0.0) 4 (100.0) - 0.20
CD4
+ cell count (cells/mm3) 1.00
350–499 1 (20.0) 0 (0.0) 1 (25.0) -
≥ 500 4 (80.0) 1 (100.0) 3 (75.0) -
Previous chlamydia episode 12 (52.2) 3 (42.9) 4 (57.1) 5 (55.6) 1.00
Chlamydia in preceding 6 months 3 (13.0) 0 (0.0) 1 (14.3) 2 (22.2) 0.75
Symptoms or signs at examinationb,c 13 (56.5) 6 (85.7) 3 (42.9) 4 (44.4) 0.23
Median time to inclusion, days (IQR) 8 (0–12) 0 (0–0) 10 (7–13) 9 (8–12) 0.003
Treatment at inclusiond 0.001
Ceftriaxone + azithromycin 16 (69.6) 7 (100.0) 1 (14.3) 8 (88.9)
Ceftriaxone + doxycycline 7 (30.4) 0 (0.0) 6 (85.7) 1 (11.1)
IQR interquartile range, MSM men who have sex with men, HIV human immunodeficiency virus, cART combination antiretroviral therapy
aUnless otherwise indicated
bSymptoms included: discharge, itch, burning, frequent or painful urination, bleeding, abdominal pain, pain during sex, anal cramps or pain, and
changed defecation
cSigns included: red urethra, discharge, bleeding, fragile mucosa, swelling or anal ulcerations
d1 patient was negative for Chlamydia trachomatis at the initial visit and therefore received ceftriaxone mono-therapy. The test at inclusion was positive and
doxycycline was started 6 days after inclusion; therefore the start of the study for the C. trachomatis analysis in this patient was day 6, and the treatment
was ceftriaxone + doxycycline
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DNA during follow-up, and there were no reinfections.
We could not determine the exact day of clearance
for one patient (Table 2). The median time to clear-
ance of the 21 patients was 6 days (range 1–15), and
95 % of patients had cleared DNA at day 14
(Fig. 1b).
Because of the small sample size the power to
detect associations with clearance is very limited. Cox
regression analyses showed no significant associations
with clearance, and Kaplan-Meier curves with log-
rank testing showed no significant difference in clear-
ance by anatomical site or treatment.
Blips after clearance of C. trachomatis
After clearance of RNA, eight patients experienced 18
blips (Table 2). After clearance of DNA, five patients ex-
perienced seven blips, of which three (all vaginal sam-
ples) coincided with RNA blips (Table 2). Among the
patients with blips, sex after clearance was reported by
five (RNA) and three (DNA) patients. We observed both
RNA and DNA blips among vaginal samples, while we
observed only RNA blips among rectal samples, and no
blips among urine samples.
When analysing all samples after clearance (411 for
RNA and 403 for DNA), the median number of days at










Patients 23 7 (30.4) 7 (30.4) 9 (39.1)
Behaviour after inclusion
Median no. of samples collected (range) 28 (25–28) 28 (26–28) 28 (26–28) 27 (25–28) 0.01
Patients with missed samples 11 (47.8) 1 (14.3) 2 (28.6) 8 (88.9) 0.009
Median no. of missed samples (IQR) 1 (1–3) 2 (2–2) 1.5 (1–2) 1 (1–3) 0.86
Rectal/vaginal douching 4 (25.0)g - 3 (42.9) 1 (11.1) 0.26
Sexual contact 12 (52.2) 3 (42.9) 4 (57.1) 5 (55.6) 1.00
Condomless sex 5 (21.7) 1 (14.3) 2 (28.6) 2 (22.2) 1.00
RNA clearanceb
Clearance during follow-up 23 (100.0) 7 (100.0) 7 (100.0) 9 (100.0)
Day of clearance definablec 21 (91.3) 7 (100.0) 6 (85.7) 8 (88.9) 1.00
Median time to clearance, days (range) 7 (1–13) 5 (1–13) 6.5 (5–9) 8 (6–13) 0.20
Blipsd
Samples at risk for blip 411 140 126 145
Number of blips 18 0 12 6
Number of patients 8 (34.8) 0 (0.0) 3 (42.9) 5 (55.6) 0.09
Median time to first blip from being at risk, days (range) 1 (1–16) - 1 (1–2) 4.5 (1–16) 0.61
DNA clearanceb,e
Clearance during follow-up 22 (100.0) 6 (100.0) 7 (100.0) 9 (100.0)
Day of clearance definablef 21 (95.5) 6 (100.0) 7 (100.0) 8 (88.9)
Median time to clearance, days (range) 6 (1–15) 6 (1–14) 5 (2–9) 7.5 (5–15) 0.08
Blipsf
Samples at risk for blip 403 117 138 144
Number of blips 7 0 0 7
Number of patients 5 (22.7) 0 0 5 (55.6) 0.01
Median time to first blip from being at risk, days (range) 3 (2–8) - - 3 (2–8)
Mean Ct-value (range) 38.6 (35.3–41.7) - - 38.6 (35.3–41.7)
RNA ribonucleic acid, DNA deoxyribonucleic acid; IQR inter-quartile range; Ct cycle threshold
aUnless otherwise indicated
bBased on a definition of 3 consecutive negative tests following a positive test
cFor 2 patients the exact day of clearance could not be defined due to missing samples in the period of clearance
dBlip was defined as a positive test following clearance. Samples from all 23 patients were included; for those without an exact day of clearance due to missing
samples, all samples after the first three consecutive negative results were considered at risk for blips
eOne patient was excluded from this analysis because the sample at inclusion was negative for Chlamydia trachomatis DNA
fFor 1 patient the exact day of clearance could not be defined due to missing samples in the period of clearance
gRectal/vaginal douching was only reported on by the 16 patients with rectal/endocervical infection
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risk per patient was 19 (range 12–25) for RNA, and
20 (range 11–25) for DNA. The overall risk of finding
a blip after clearance was 4.4 % per day for RNA and
1.7 % per day for DNA. DNA blips had significantly
higher Ct-values (mean: 38.6, range: 35.3–41.7) com-
pared to pre-treatment samples (mean: 31.6, range:
27.8–39.3, P < 0.001). Only two RNA blips and two
DNA blips were observed within 24 h of reported
sex, of which one was a blip in both RNA and DNA
testing (Fig. 2).
Although the sample size was relatively small, we de-
termined characteristics associated with blips using GEE
logistic regression. RNA blips were significantly associ-
ated with HIV-positivity (odds ratio [OR]: 8.0, 95 % con-
fidence interval [95 %-CI]: 2.3–28.1, P = 0.001), a
chlamydia infection in the previous 6 months (OR: 6.6,
95 %-CI: 1.8–24.7, P = 0.005), and with absence of symp-
toms or signs (OR: 0.17, 95 %-CI: 0.03–0.97, P = 0.05).
In multivariable analysis, HIV-status and previous chla-
mydia infection remained significantly associated (OR:
7.1, 95 %-CI: 2.5–19.9, P < 0.001, and OR: 5.9, 95 %-CI:
2.2–16.3, P = 0.001, respectively). As there were seven
DNA blips, the power for this analysis was limited; only
sexual contact in the 24 h before sampling was signifi-
cantly associated in univariable analysis (OR: 6.8, 95 %-
CI: 1.3–36.7, P = 0.03).
Discussion
In this study we analysed the time to clearance of ano-
genital C. trachomatis after treatment in patients coin-
fected with N. gonorrhoeae, using modern RNA- and
DNA-based NAATs and daily collected samples. The
median time to clearance was 7 days for RNA and 6 days
for DNA. Ninety-five per cent of patients had cleared C.
trachomatis RNA and DNA after 13 and 14 days,
respectively.
Several previous studies reported on in vivo clearance
of C. trachomatis after treatment, but used different mo-
lecular testing methods, and a sampling frequency of no
more than twice a week. Some studies observed clear-
ance of DNA within 3 weeks using ligase chain reaction
or in-house PCR methods [13, 14], while other studies
reported 5–25 % DNA persistence after 3–4 weeks [9,
15, 16, 25]. The exact time to clearance of RNA, when
tested by NAAT, was also previously unknown. Sena et
al. reported 12 % RNA persistence after 4 weeks in men,
while Dukers et al. reported 42 % intermittent positive
results up to 51 days [9, 19]. In addition, a recent study
reported 24 % positivity in 180 patients after 6 months,
but no data on re-exposure or reinfections were reported
[26]. Since none of these previous studies reported re-
sults from consecutive days, the exact time to clearance
could not be determined, and prolonged persistence
could not be distinguished from blips. In addition, none
reported data on events that could have caused reinfec-
tion, like was done in the current study. Although no
previous studies have been performed on the clearance
of C. trachomatis in patients coinfected with N. gonor-
rhoeae, our results confirm the assumption that C.
trachomatis RNA and DNA are cleared after 2 weeks
[14, 17, 25].
Intermittent positive results or blips have been previ-
ously described by several studies; between 5 and 18 %
of patients had a positive test result following a previous
negative result after treatment [9, 14, 17–19]. We report
an overall risk of blips after clearance of almost 2 % for
DNA and 4 % for RNA, and no treatment failures or re-
infections. The slightly higher sensitivity of the RNA test
could explain the higher frequency of RNA blips, com-
pared to DNA blips. The fact that all but one of the pre-
treatment samples initially diagnosed by RNA testing
were also positive for DNA, makes it unlikely that the
different sensitivity is of clinical importance in diagnos-
ing chlamydia. On the other hand, when performing a
TOC, higher sensitivity could result in more positive re-
sults. The implications of this should be clarified in lar-
ger studies. Unfortunately, NAAT testing only gives
information about the presence of genetic material, but
not on the viability of the pathogen or whether this is
still infectious. Therefore blips could be the result of de-
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Fig. 1 Time to clearance of Chlamydia trachomatis RNA (a) and DNA
(b). The horizontal line represents 95 % clearance. RNA, ribonucleic
acid; DNA, deoxyribonucleic acid
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sexual partner, release of genetic material by degrading
cells, or possibly the presence of elementary bodies that
hold genetic components of C. trachomatis [18, 27]. The
origin of blips needs to be further examined in future re-
search. Due to the small sample size we could not iden-
tify characteristics associated with the occurrence of
blips. However, the occurrence of blips, as well as rein-
fections, could explain the higher positivity rates re-
ported by some studies, especially in those with very
long follow-up and limited sampling [9, 15, 18, 19, 26].
Our study has several limitations. It was performed at
a single centre in a high-incidence population, which
may limit the generalizability. We selected patients from
a cohort infected with N. gonorrhoeae, so this concerns a
population coinfected with N. gonorrhoeae and C. tra-
chomatis, which may influence both time to clearance
and the occurrence of blips. Because all patients were
coinfected with N. gonorrhoeae, they were also treated
with ceftriaxone. Since ceftriaxone is not effective
against chlamydia, it is unlikely that treatment with cef-
triaxone influenced the clearance of C. trachomatis.
Nevertheless, confirmation of our results in chlamydia
monoinfected patients is warranted.
Conclusions
Our results are the first to show that C. trachomatis RNA
and DNA are cleared within 14 days of initiating treatment,
using daily testing. Despite the small sample size, our re-
sults suggest that if a TOC is indicated in patients with C.
trachomatis and N. gonorrhoeae coinfection, it is best per-
formed after at least 2 weeks. Positive results obtained more
than 2 weeks after initiation of treatment should be evalu-
ated carefully, as these probably represent blips, and do not
necessarily indicate treatment failure or reinfection. To ex-
clude blips as the cause of a positive TOC, we recommend
to obtain a new sample for retesting.
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